NCT06248554Completed
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation: a Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
For early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection. However, ablation is demanding on the surgeon and patients often face early recurrence if ablation is not complete. Therefore, it is necessary to find reasonable adjuvant treatment to consolidate the effect of microwave therapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 251 (actual)
- First submitted
- 31 Jan 2024
- Start date
- 1 Jan 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Chen Xiaoping
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06248554
What you commit to
- Study type: Interventional
- Participants enrolled: 251
- From 1 Jan 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any preoperative treatment for HCC including local and systemic therapy
Other illness
- Any history of other malignant tumors or recurrent HCC
- Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency
- Esophageal and/or gastric variceal bleeding within 6 months
Other
- Any persistent serious ablation-related complications
- Inability or refusal to comply with the treatment and monitoring
- Participation in other clinical trials
Who the study is looking for
- Aged 18-75 years
- Pathological type is HCC, BCLC stage 0-A
- No extrahepatic HCC
- No radiographic recurrence at 2-4 weeks after ablation
- Eastern Cooperative Oncology Group (ECOG) performing status of 0-1
- Child-Pugh grade A or B and adequate hematologic and organ function
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.